Giuseppe Viscardi
@giuseppeviscardi.bsky.social
MD, PhD. Medical oncologist. Lung cancer specialist. AIOM giovani working group. Naples IT
Reposted by Giuseppe Viscardi
Hello, #MedSky community! We’re excited to begin our Bluesky journey.
Here is a sampling of the trusted, influential, and essential information you can expect when you follow us:
Here is a sampling of the trusted, influential, and essential information you can expect when you follow us:
December 6, 2024 at 8:24 PM
Hello, #MedSky community! We’re excited to begin our Bluesky journey.
Here is a sampling of the trusted, influential, and essential information you can expect when you follow us:
Here is a sampling of the trusted, influential, and essential information you can expect when you follow us:
69% five-years survival rate with perioperative chemo-immunotp in resectable stage III NSCLC: NADIM trial establishes a new milestone
www.thelancet.com/journals/lan...
www.thelancet.com/journals/lan...
Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial
Perioperative chemoimmunotherapy showed a promising long-term benefit with no concerning safety data, reinforcing its use in resectable stage IIIA NSCLC.
www.thelancet.com
December 6, 2024 at 9:03 PM
69% five-years survival rate with perioperative chemo-immunotp in resectable stage III NSCLC: NADIM trial establishes a new milestone
www.thelancet.com/journals/lan...
www.thelancet.com/journals/lan...